- Home
- NRDS vs GYRE Comparison
NRDS vs GYRE Comparison
Compare NRDS & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- GYRE
- Stock Information
- Founded
- NRDS 2009
- GYRE 2002
- Country
- NRDS United States
- GYRE United States
- Employees
- NRDS N/A
- GYRE N/A
- Industry
- NRDS EDP Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- GYRE Health Care
- Exchange
- NRDS Nasdaq
- GYRE Nasdaq
- Market Cap
- NRDS 785.4M
- GYRE 897.1M
- IPO Year
- NRDS 2021
- GYRE N/A
- Fundamental
- Price
- NRDS $10.42
- GYRE $8.18
- Analyst Decision
- NRDS Buy
- GYRE
- Analyst Count
- NRDS 5
- GYRE 0
- Target Price
- NRDS $13.80
- GYRE N/A
- AVG Volume (30 Days)
- NRDS 596.5K
- GYRE 77.8K
- Earning Date
- NRDS 08-07-2025
- GYRE 08-11-2025
- Dividend Yield
- NRDS N/A
- GYRE N/A
- EPS Growth
- NRDS N/A
- GYRE N/A
- EPS
- NRDS 0.60
- GYRE 0.02
- Revenue
- NRDS $771,200,000.00
- GYRE $102,189,000.00
- Revenue This Year
- NRDS $18.07
- GYRE $21.04
- Revenue Next Year
- NRDS $8.22
- GYRE $89.64
- P/E Ratio
- NRDS $17.38
- GYRE $176.20
- Revenue Growth
- NRDS 28.75
- GYRE N/A
- 52 Week Low
- NRDS $7.55
- GYRE $6.11
- 52 Week High
- NRDS $16.45
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- NRDS 50.56
- GYRE 58.07
- Support Level
- NRDS $9.89
- GYRE $7.35
- Resistance Level
- NRDS $10.31
- GYRE $8.30
- Average True Range (ATR)
- NRDS 0.39
- GYRE 0.45
- MACD
- NRDS 0.00
- GYRE 0.08
- Stochastic Oscillator
- NRDS 69.44
- GYRE 92.86
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.